Coordinated by GU Ventures
Commercializing New Modalities
Can leading organizations collaborate to ensure access to quality resources, engage with complementary organizations, and facilitate access to capital? We believe so!
A Unique Constellation of Life Science Organizations
New Modality Support (NMS) is a collaborative project supporting individual research within the national drug development initiatives OligoNova and CCRM Nordic. It focuses on therapeutic oligonucleotides and advanced therapies (ATMP). The constellation members combine their unique strengths to support early-stage life science companies in the Nordic region.
Utilizing research is crucial. Our researchers’ ideas and solutions can contribute to a better future—if given the opportunity to realize them. NMS plays an important role in achieving this
Jenny Nyström
Dean and Professor of Physiology at the Sahlgrenska Academy, the Medical faculty at University of Gothenburg
NMS acts as an entrepreneurial catalyst that provides drug development support and serves as a valuable hub of expertise for researchers and their projects as they progress towards clinical application
Klementina Österberg
CEO, GU Ventures
Although OligoNova and CCRM Nordic operate in relatively different areas and development stages, there are significant opportunities for synergies and collaboration
Fredrik Wessberg
CEO, CCRM Nordic
Combining and building on our respective skills and strengths will leverage these unique assets to create new and competitive global companies. NMS is a crucial component in this formula and a central resource for the academic drug projects that we support
Pär Matsson
Professor, Sahlgrenska Academy and Scientific Director, OligoNova Hub
Within the area that NMS addresses, we already have established and good relationships with healthcare, industry, and academia. We will build on these to ensure that healthcare and patient perspectives become integral parts of the development of new, advanced drugs.
Kristina Levan
Director of Sahlgrenska ATMP center, Sahlgrenska University Hospital
Jenny Nyström
Dean and Professor of Physiology at the Sahlgrensk...
Klementina Österberg
CEO, GU Ventures
Fredrik Wessberg
CEO, CCRM Nordic
Pär Matsson
Professor, Sahlgrenska Academy and Scientific Dire...
Kristina Levan
Director of Sahlgrenska ATMP center, Sahlgrenska U...
Sharing Knowledge to Provide Better Support
Success in therapeutic oligonucleotide and ATMP-specific drug development requires new knowledge and understanding. Incorporating research and commercialization strategies early increases a project’s chance of success.
Sector
Expertise
We simplify the process of collaborating with specialists, including regulatory pathway expertise, as well as finding resources, programs and assistance available to help new and early-stage businesses.
Funding and Investments
Attractive and clear packaging of the investment case is important in order attract relevant investors. We help early-stage businesses navigate the investor landscape and build strong investor-company relationships.
Fostering Collaboration
NMS helps early-stage businesses in getting access to complementary organizations within the life science ecosystem such as incubators, arenas, hospitals and universities.
